Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.53 |
| ▸ | EGFR | P00533 | 10/20 | 0.47 |
| ▸ | FLT1 | P17948 | 9/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497364 | 1.00 | ERBB2 (0.53) | ERBB2EGFRFLT1KDRKDM4E | |
| SCHEMBL6483679 | 0.91 | EGFR (0.51) | ERBB2EGFR | |
| SCHEMBL6483676 | 0.91 | EGFR (0.51) | ERBB2EGFR | |
| SCHEMBL6498655 | 0.89 | EGFR (0.41) | ERBB2EGFRFLT1KDR | |
| SCHEMBL6498661 | 0.89 | EGFR (0.41) | ERBB2EGFRFLT1KDR | |
| SCHEMBL6485329 | 0.86 | ERBB2 (0.56) | ERBB2EGFRFLT1KDRKDM4E | |
| Hydrochloric Acid SCHEMBL6483348 | 0.86 | ERBB2 (0.47) | ERBB2EGFRFLT1KDR | |
| SCHEMBL6484671 | 0.86 | FLT1 (0.49) | ERBB2EGFRFLT1KDR | |
| SCHEMBL6484674 | 0.86 | FLT1 (0.49) | ERBB2EGFRFLT1KDR | |
| SCHEMBL6496925 | 0.83 | ERBB2 (0.49) | ERBB2EGFRFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | claimed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 20/4885FLT1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.